新辅助化疗期间乳腺MRI背景实质强化未抑制与治疗反应不佳相关
本研究基于I-SPY 2试验的回顾性数据,纳入882例乳腺癌患者共3528次乳腺增强MRI,采用自动纤维腺体组织分割定量测量背景实质强化(BPE)。结果显示在激素受体阳性患者中,化疗间期和术前BPE未抑制与较低的病理完全缓解率相关,而激素受体阴性患者中该关联无统计学意义。
要点
- 激素受体阳性乳腺癌患者新辅助化疗后BPE未抑制提示治疗反应较差。
- BPE抑制评估可辅助判断新辅助化疗疗效,尤其对激素受体阳性患者。
- 激素受体阴性患者中BPE未抑制与pCR的关联未达统计学显著。
局限性
- 回顾性研究设计。
- 仅纳入高质量BPE分割子集进行分析。
- 激素受体阴性队列中关联未达统计学显著。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Background Suppression of background parenchymal enhancement (BPE) is commonly observed after neoadjuvant chemotherapy (NAC) at contrast-enhanced breast MRI. It was hypothesized that nonsuppressed BPE may be associated with inferior response to NAC. Purpose To investigate the relationship between lack of BPE suppression and pathologic response. Materials and Methods A retrospective review was performed for women with menopausal status data who were treated for breast cancer by one of 10 drug arms (standard NAC with or without experimental agents) between May 2010 and November 2016 in the Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging and Molecular Analysis 2, or I-SPY 2 TRIAL (NCT01042379). Patients underwent MRI at four points: before treatment (T0), early treatment (T1), interregimen (T2), and before surgery (T3). BPE was quantitatively measured by using automated fibroglandular tissue segmentation. To test the hypothesis effectively, a subset of examinations with BPE with high-quality segmentation was selected. BPE change from T0 was defined as suppressed or nonsuppressed for each point. The Fisher exact test and the Z tests of proportions with Yates continuity correction were used to examine the relationship between BPE suppression and pathologic complete response (pCR) in hormone receptor (HR)-positive and HR-negative cohorts. Results A total of 3528 MRI scans from 882 patients (mean age, 48 years ± 10 [standard deviation]) were reviewed and the subset of patients with high-quality BPE segmentation was determined (T1, 433 patients; T2, 396 patients; T3, 380 patients). In the HR-positive cohort, an association between lack of BPE suppression and lower pCR rate was detected at T2 (nonsuppressed vs suppressed, 11.8% [six of 51] vs 28.9% [50 of 173]; difference, 17.1% [95% CI: 4.7, 29.5]; P = .02) and T3 (nonsuppressed vs suppressed, 5.3% [two of 38] vs 27.4% [48 of 175]; difference, 22.2% [95% CI: 10.9, 33.5]; P = .003). In the HR-negative cohort, patients with nonsuppressed BPE had lower estimated pCR rate at all points, but the P values for the association were all greater than .05. Conclusions In hormone receptor-positive breast cancer, lack of background parenchymal enhancement suppression may indicate inferior treatment response. © RSNA, 2021 Online supplemental material is available for this article. See also the editorial by Philpotts in this issue.
引用
- Onishi N, Li W, Newitt DC, et al. Breast MRI during Neoadjuvant Chemotherapy: Lack of Background Parenchymal Enhancement Suppression and Inferior Treatment Response. Radiology. 2021. PMID: 34427465. doi:10.1148/radiol.2021203645
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。